PREDICT-ILD: A Study Looking at ILD Progression with Computer Technology

Upcoming study
Expected to open June 2023
This study is currently recruiting
Expected to close
This study is closed
This study closed in
We will update this page with study results when available.
Information on study results are included below
This study closed in
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

Progression of disease for people with fibrotic lung diseases, such as pulmonary fibrosis, is often unpredictable. Lung function test are part of standard care, and used to see how the disease is progressing over time. This doesn't always give a reliable picture of how things really are, as there can be difficulties when doing the tests.

High resolution computed tomography (HRCT) scans are used for diagnosis. Results are reported by trained radiologists, which can be limited by how each person interprets what they can see. A quantitative CT approach uses computer technology to analyse the HRCT results.

This study wants to understand if the new computer technology can predict and identify disease progression in fibrotic-ILD.


What is involved?

You will be asked to take part at one of 3 centres in England, along with healthy control participants. You will have tests at the start of the study, 6-months and 12-months. This will include: HRCT, lung function tests, blood tests and questionnaires to measure health-related quality of life.

Summary of involvement

Investigations at the start of the study, 6- and 12-months

HRCT scans

Lung function tests

Blood tests

Questionnaires to measure health-related quality of life

Can I take part?

You may be able to take part if you have a diagnosis of IPF or non-IPF fibrotic-ILD, are aged 18 years and over, and meet the full inclusion criteria.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the clinical trial team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Diagnosis of IPF or non-IPF fibrotic ILD

Aged 18 years and over

Able to provide informed consent

No previous antifibrotic therapy at the start of the study

You will not be able to join the study of any of the following applies:

Any other significant respiratory disease

Evidence of ILD exacerbation at the time of the CT

There is also a criteria for lung function, but this must be discussed with the research team

What difference could taking part make?

Taking part in this initial feasibility study will help researchers to understand if using quantitative CT computer analysis can provide clinical benefit for disease monitoring. The results from this study will help to inform a subsequent larger multi-centre investigation.

Where does the study take place?

Study locations




How to take part

Please speak to your healthcare team about taking part in the study and contact the researchers for more information.

Further information

The summary on this page provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

This study is supported by

Wellcome Trust
University of Exeter
Study ID number:
IRAS ID 319752

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email